当前位置: X-MOL 学术Allergol. Immunopathol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Dust mite-derived Enterobacterial fimbriae H protein enforces the allergen specific immunotherapy in asthma mice.
Allergologia et Immunopathologia ( IF 1.8 ) Pub Date : 2020-05-20 , DOI: 10.1016/j.aller.2020.03.012
X Yang 1 , H Wang 2 , D Zhao 3 , J Wang 4 , X Liu 2 , X Yuan 2 , M Zhang 2 , G Li 4 , P Ran 5 , P Yang 2 , Z Liu 6
Affiliation  

Background

The mite alimentary canal contains plenty of microbiota. It is accepted that some of the microbial products function as adjuvants to speed up immune responses.

Objectives

We identified five bacterial proteins from dust mite, and Enterobacterial fimbriae H (FimH) was one of them. This study aims to test a hypothesis that the FimH protein enforces immunotherapy in asthmatic mice.

Methods

Asthmatic mice were treated by allergen specific immunotherapy (ASIT) with rDer f1/f2 or rDer f1/f2 plus FimH. Changes in inflammatory cell infiltration, airway hyperreactivity, frequency of Tregs, splenic CD4+IFN-γ+ cells, and serum levels of TGF-β, IL-10, IL-13 and IL-17A of asthmatic mice were checked.

Results

ASIT with rDer f1/f2 plus FimH reduced inflammatory cell infiltration, airway hyperreactivity (AHR), and levels of IgE and IgG1 compared to ASIT with rDer f1/f2 alone, but the levels of IgG2a increased. Asthmatic mice that underwent ASIT with rDer f1/f2 plus FimH showed increased frequency of Tregs, splenic CD4+IFN-γ+ cells, serum levels of TGF-β and IL-10; and deceased splenic CD4+IL-4+ cells, and serum levels of IL-13 and IL-17A. In vitro study showed FimH triggered IL-10 expression in a concentration dependent manner and facilitated the differentiation of Tregs.

Conclusion

Used as an adjuvant, FimH enforces the effect of ASIT in asthmatic mice via augmenting Tregs.



中文翻译:

尘螨衍生的肠杆菌菌毛 H 蛋白在哮喘小鼠中强制执行过敏原特异性免疫治疗。

背景

螨的消化道含有大量的微生物群。公认的是,一些微生物产品起到佐剂的作用以加速免疫反应。

目标

我们从尘螨中鉴定出五种细菌蛋白质,肠杆菌菌毛 H (FimH) 就是其中之一。本研究旨在检验 FimH 蛋白对哮喘小鼠进行免疫治疗的假设。

方法

哮喘小鼠通过过敏原特异性免疫疗法 (ASIT) 与 rDer f1/f2 或 rDer f1/f2 加 FimH 进行治疗。检查哮喘小鼠的炎性细胞浸润、气道高反应性、Tregs 频率、脾 CD4 + IFN-γ +细胞以及血清 TGF-β、IL-10、IL-13 和 IL-17A 水平的变化。

结果

与单独使用 rDer f1/f2 的 ASIT 相比,使用 rDer f1/f2 加 FimH 的 ASIT 减少了炎症细胞浸润、气道高反应性 (AHR) 以及 IgE 和 IgG1 的水平,但 IgG2a 的水平增加。使用 rDer f1/f2 加 FimH 进行 ASIT 的哮喘小鼠显示 Tregs、脾脏 CD4 + IFN-γ +细胞、TGF-β 和 IL-10 的血清水平增加;和死亡的脾脏 CD4 + IL-4 +细胞,以及血清 IL-13 和 IL-17A 水平。体外研究表明,FimH 以浓度依赖性方式触发 IL-10 表达并促进 Treg 的分化。

结论

FimH 用作佐剂,通过增加 Treg 增强 ASIT 在哮喘小鼠中的作用。

更新日期:2020-05-20
down
wechat
bug